🔗 Share this article

While America proceeds with sweeping adjustments to its immunization recommendations, a particular individual has emerged somewhat surprisingly: Tracy Beth Høeg, a US-based sports medicine doctor and epidemiologist who first made her name by casting doubt on COVID-19 vaccines in the pandemic and has focused upon alleged fatalities after Covid immunization in her short time at the FDA.

Scheduled Overhauls to Pediatric Vaccine Program

Public health authorities planned to unveil major changes to the pediatric vaccine schedule in December, aligning the US with the Danish immunization schedule, it is understood – a significant shift that would place the US out of alignment with much of the global community with little proof for public health gain. This reveal has been delayed until the new year.

Rather than the top vaccines chief, Høeg is set to address the audience at the gathering. She was newly appointed interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to lead the center this year.

A New Direction at the Agency

This interim role may indicate a tighter collaboration between the pharmaceutical and vaccine centers as Høeg and Prasad solidify control at the regulatory agency – and it signals a greater focus upon rolling back already-approved vaccines at the FDA.

Høeg has often pushed for ending some pediatric vaccine recommendations in the US to become more like Denmark, a country with comprehensive healthcare and a number of inhabitants approximately the population of Wisconsin’s.

To date comments, she has kept her attention on vaccines – traditionally the domain of Dr. Prasad, chief of the FDA’s CBER – instead of drug regulation.

Doubts Over Background

Dr. Høeg has little discernible background in pharmaceutical research, regulation or administrative roles, which has been standard for former directors of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a top consultant to the agency head and the vaccine center since March.

“She appears not to have the necessary background” for overseeing the drug-regulation department, said Dr. Jonathan Howard. “She lacks experience running a clinical trial. She is not versed in managing a large organization. She lacks background in pharmaceutical oversight.”

Former commissioners of the center would “grasp regulatory frameworks and the underlying principles of drug development”, noted Janet Woodcock. “Frankly, she lacks the sort of resume that previous people who headed the center have had.”

This division has an immense range of responsibilities at the FDA, the former commissioner pointed out.

“Many people just zeroes in on the novel medication approvals, but the generic drug division authorizes numerous generic drugs. There’s a biosimilars division, OTC medication office and more, and each of these need to be looked after,” Woodcock noted. “The area you overlook, that’s the thing that I always told people is going to cause problems.”

Furthermore, a significant leadership element to the role, which manages in excess of 5,000 personnel. “It’s a enormous management job, if you perform it correctly,” she added.

Official Statement and Disputed Policies

Regarding concerns about Dr. Høeg's qualifications and whether this appointment represents increased cooperation among regulatory chiefs on immunizations, a spokesperson responded that the “questions rely on incorrect presumptions”.

“Her resume aligns with the duties of her job,” the official said, noting the period Dr. Høeg spent guiding the FDA commissioner on “drug safety and regulatory science, including computational safety modeling and vaccine surveillance”.

As the temporary head, Høeg assumes responsibility for the commissioner’s new fast-track approval initiative, a controversial expedited drug-approval program that allegedly worried her preceding directors. “By what process are these drugs being picked for this expedited pathway? Who makes the calls?” Dr. Howard said. “There is a lot of lack of transparency happening at the agency right now.”

Broadly speaking, he remarked, “the agency seems to be moving towards laxer rules of pharmaceuticals, with the exception of immunizations.”

Established History on Vaccines

Regarding immunizations, Høeg has a clearer, if troubling, history, critics observe. She published a analysis using unverified volunteer-provided data to assess the frequency of myocarditis following COVID-19 immunization. She advised the Florida chief medical officer Dr. Joseph Ladapo, who was said to have changed statistics to indicate COVID-19 vaccines are more dangerous than they are.

Among her “wish list” for the current administration encompassed changing rules for novel immunizations and ending “non-essential” vaccines, she remarked following the vote on a online show. At the FDA, Høeg has according to sources suggested preventing adolescent males from obtaining COVID-19 vaccinations.

“She’s an all-around ideologue who commences with her conclusions and works backwards to accommodate the data in a very misleading, untruthful way,” Dr. Howard stated.

Gaining Influence and a “Revenge Tour”

Dr. Høeg aligned with other contrarians, {like|